Replies to post #28253 on Marker Therapeutics Inc (MRKR)

[poods]

It's a good one to hold IMO and you're not likely going to need to wait for an approval for substantial SP appreciation. Look at the price of cellular I-O companies (Allogene, Iovance, etc.). Prices rise when approvals seem more likely to the market. MRKR just needs to convince the market that the platform works and the MC should rise into the multibillion range, as with these other companies.
Frankly, I'm not sure what it will take to convince the market this is working. Maybe another CR in pancreatic cancer or a couple of more lymphoma CRs. Hard to say what will trigger the awakening.

[TuiTui509]

Thank you Phantom!!! As always appreciate your thoughts.

I currently have 30k in my stock account with chase and another close to 10k in my ROTH.

I am with you I won’t sell a single share until the company fundamentals shifts downwards.

With great science team and managment team, I believe there should not be anything dramatic except an event like FDA rejection or such. Which from the data we currently have/had, that scenario won’t fold into count.

The only thing left is company financial factor. We are beaten down over and over since TPIV was because we could not acquire substantial fundings for long term. And I believe that is the main reason the MC is trading this low.

We are in a way better spot than before in the TPIV era financially I admit but still that is only factor that stops the street analysts give us higher price target that MRKR truly deserve. Allogene to date still have over 600 millions in cash from the IPO, and burn rate is 35-40 per quarter. With that strong financial of course its MC will trade way higher than MRKR.

if we don’t get back fire or poor decision made on the shelf, I could not see the PPS going under $6 long term.

Anyway, thank you for your thoughts.